Literature DB >> 9796854

Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome.

L S Tam1, E K Li.   

Abstract

Severe pulmonary hypertension (PHT) occurring in patients with systemic lupus erythematosus (SLE) is uncommon. Different modalities have been tried in the treatment for this condition but have not been effective because of progressive increase of pulmonary resistance over time. Our patient with SLE and PHT with antiphospholipid syndrome (APS), a condition which has previously never been described, responded rapidly to combination treatment with immunosuppression, anticoagulation and vasodilator therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796854     DOI: 10.1191/096120398678920442

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

Review 1.  Pleuropulmonary manifestations of systemic lupus erythematosus.

Authors:  M P Keane; J P Lynch
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

2.  Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.

Authors:  Shikha Mittoo; Thomas Jacob; Andrea Craig; Zoheir Bshouty
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

Review 3.  The lung in the antiphospholipid syndrome.

Authors:  G Espinosa; R Cervera; J Font; R A Asherson
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

4.  Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide.

Authors:  Eri Sugawara; Masaru Kato; Ryo Hisada; Kenji Oku; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Intern Med       Date:  2017-02-15       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.